RxDoctor Payments Data

Dean Ouano, MD

Ophthalmology · New Bern, NCNPI 1811911316

Payments from drug & device makers

$2,158in general payments, 2019–2025

Across 93 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$241
  • AbbVie$218
  • Johnson & Johnson Surgical Vision, Inc.$202
  • Amgen$181
  • Tarsus Pharmaceuticals, Inc.$168
  • Sun Pharmaceutical Industries Inc.$159
  • plus $989 from 17 others

What the payments were for

  • Food & beverage$2,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,158 in reported general payments places this provider in the 55th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$434,001
Medicare patients
1,200
Services billed
3,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium123$41,951
LumiganBimatoprost66$29,410
Prednisolone Acetate663$26,921
RestasisCyclosporine25$25,300
CombiganBrimonidine Tartrate/Timolol24$13,206
ZirganGanciclovir12$5,459
Ofloxacin409$5,245
ValacyclovirValacyclovir Hcl88$5,199
Fluorometholone61$4,968
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat214$4,374
Timolol Maleate403$4,234
Bromfenac Sodium20$3,362
SimbrinzaBrinzolamide/Brimonidine Tart15$3,132
Brimonidine Tartrate93$3,077
Loteprednol Etabonate14$3,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$218$67,917115 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$55$44,968137 claims
Bausch & Lomb Americas Inc.Zirgan$156$5,45912 claims
AlconSimbrinza$241$3,13215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →